PT  - JOURNAL ARTICLE
AU  - Hayashi, Takuma
AU  - Sano, Kenji
AU  - Konishi, Ikuo
TI  - High transferability of neutralizing antibodies against SARS-CoV-2 to umbilical cord blood in pregnant women with BNT162b2 XBB.1.5 vaccine - a retrospective cohort study
AID  - 10.1101/2024.03.18.24304517
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.03.18.24304517
4099  - http://medrxiv.org/content/early/2024/03/19/2024.03.18.24304517.short
4100  - http://medrxiv.org/content/early/2024/03/19/2024.03.18.24304517.full
AB  - Coronavirus disease 2019 (COVID-19), when contracted by pregnant women, can lead to severe respiratory illness, rapid disease progression, and higher rates of intensive care unit admission. COVID-19 infection during pregnancy is associated with an increased risk of preterm delivery, cesarean section, fetal dysfunction, preeclampsia, and perinatal death. Additionally, vertical transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from pregnant women to their fetuses has been observed. While severe infections in neonates and infants are rare, newborns can experience serious consequences from COVID-19, despite their suboptimal humoral immune system protection. The amino acids in the structural proteins of SARS-CoV-2 are subjected to constant mutation. Since around January 2023, COVID-19, caused by infection with omicron-type SARS-CoV-2 variants, has been prevalent globally. Omicron-type SARS-CoV-2 variants can evade the immune response triggered by traditional mRNA-based COVID-19 vaccines, such as BNT162b2. Therefore, vaccination with a vaccine (BNT162b2 XBB.1.5) that can provide protection against omicron-type SARS-CoV-2 variants is recommended. Therefore, we examined the titers of anti-spike glycoprotein of SARS-CoV-2 IgG and IgA in the blood and umbilical cord blood obtained from pregnant women vaccinated with BNT162b2 XBB.1.5. The results showed that anti-spike glycoprotein of SARS-CoV-2 IgG and IgA titers were highest in the blood and cord blood obtained from pregnant women vaccinated with BNT162b2 XBB.1.5 at late gestational age (28–34 weeks). No serious side effects or adverse events caused by vaccination of pregnant women with BNT162b2 XBB.1.5 were observed in either pregnant women or newborns. In the future, to validate our findings, large cohort clinical studies involving numerous pregnant women must be conducted.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis clinical research was performed with research funding from the following: Japan Society for Promoting Science for TH (Grant No. 19K09840), START-program Japan Science and Technology Agency for TH (Grant No. STSC20001), and the National Hospital Organization Multicenter clinical study for TH (Grant No. 2019-Cancer in general-02), and The Japan Agency for Medical Research and Development (AMED) (Grant No. 22ym0126802j0001), Tokyo, Japan.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We conducted a multi-center retrospective observational clinical study involving participants who underwent cancer genomic medicine at cancer medical facilities in Kyoto, Japan. This study was reviewed and approved by the Central Ethics Review Board of the National Hospital Organization Headquarters in Japan (Tokyo, Japan) on November 18, 2020 (Approval code NHO R4-04) and by the Kyoto University School of Medicine (Kyoto, Japan) on August 24, 2022 (Approval code M237). All participants provided their informed consent to participate in this study. Our clinical research adheres to the principles outlined in the Helsinki Statement. Institutional Review Board Statement and Consent to Participate: The experiments involving human cancer genome information obtained from results by cancer genome gene panels were conducted at Kyoto University, affiliated hospitals, and the National Hospital Organization Kyoto Medical Center in accordance with institutional guidelines. The study received approval from the Institutional Review Board (IRB) of Kyoto University (Approval code M192, H31-cancer-2) on April 05, 2014, and June 16, 2016, and the IRB of National Hospital Organization Headquarter (Approval code H31-cancer-2) on November 09, 2019, and June 17, 2022. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscriptCOVID-19Corona Virus Infectious Disease, emerged in 2019NIHNational Institution HealthIgGimmunoglobulin GSARS-CoV-2severe acute respiratory syndrome coronavirus-2